Clinical trials: Radiographic Contrast Agent Nephropathy
Radiographic Contrast Agent Nephropathy
Relationship Between ALDH2 and CIN
The purpose of this clinical trial is to investigate the relationship between the gene polymorphism of aldehyde dehydrogenase 2 and contrast induced nephropathy and its mechanism.
- Trial name
- REACTION (NCT02643706)
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Qilu Hospital of Shandong University
Radiographic Contrast Agent Nephropathy, Renal Failure
Prevention of Contrast Nephropathy During Diagnostic Coronary Angiogram or PCI With Hydratation Based on LEVDP
The goal is to determine if prehydration based on LEVDP is superior to a standard hydratation with NaCl 0.9% or NaHCO3 for the prevention of contrast nephropathy related to a diagnostic coronary angiogram or to PCI.
- Conditions
- Radiographic Contrast Agent Nephropathy, Renal Failure, Coronary Heart Disease
- Trial name
- NEPHRON (NCT00584350)
- Testing
- Hydratation according LVEDP + NaHCO3, normal saline, Sodium bicarbonate
- Where
- Canada
- Volunteers
- 330 people
- Sponsor
- Université de Sherbrooke
Radiographic Contrast Agent Nephropathy, Pulmonary Embolism
NAC, NaHCO3 and NS Prophylaxis for CTPA in the ED on Suspicion of PE: A Randomized Controlled Trial
Study objective: The purpose of this study was to compare the role of the prophylactic protocols N-acetylcysteine (NAC) plus normal saline, sodium bicarbonate (NaHCO3) plus normal saline and intravenous normal saline (NS) alone…
- Trial name
- NCT02483143
- Testing
- NAC, NaHCO3, Normal Saline
- Where
- Turkey (Türkiye)
- Volunteers
- 231 people
- Sponsor
- Karadeniz Technical University
Contrast-induced Nephropathy, Coronary Angiography
Relative Bioavailability of CE-Iohexol (Captisol-enabled™ Iohexol) Injection and Omnipaque™ Injection
This study is designed to compare the bioavailability of the test Product(CE-Iohexol Injection) and the reference product Iohexol Injection (Omnipaque™) following intravenous injection in normal healthy volunteers.
- Trial name
- NCT03869983
- Testing
- Omnipaque™ (iohexol) Injection, CE-Iohexol
- Where
- Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- CyDex Pharmaceuticals, Inc.
Radiographic Contrast Agent Nephropathy
Comparing Effects of Patient-specific Versus Non-patient-specific Computerized Reminder System
The investigators hypothesize that a Clinical Decision Support System (CDSS) designed with "Patient-Specific" reminders yields superior performance than that with "Non-patient-specific" reminders in preventing contrast-induced…
- Trial name
- NCT01778140
- Testing
- Patient-specific computerized reminder, Non-patient-specific computerized reminder
- Where
- Taiwan
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Taipei Medical University
Radiocontrast-induced Nephropathy
Mechanisms for the Effect of Acetylcysteine on Renal Function After Exposure to Radiographic Contrast Material
Millions of people receive radiographic contrast material for investigations like CT and coronary angiography. While considered safe in healthy patients, it can cause acute renal impairment.
- Trial name
- NCT00558142
- Testing
- Acetylcysteine, Visipaque 320
- Where
- United Kingdom
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- University of Edinburgh
Radiographic Contrast Agent Nephropathy
Prevention of Contrast Induced Nephropathy in Oncology Patients With Sodium Bicarbonate
Contrast induced nephropathy is a rising cause of acute renal failure in all patients. A study published in JAMA 2004, show a superiority of a hydratation with sodium bicarbonate in comparison with the same volume hydratation…
- Trial name
- NCT00540904
- Testing
- sodium bicarbonate, NaCl
- Where
- Brazil
- Volunteers
- 27 people
- Sponsor
- Barretos Cancer Hospital
Chronic Kidney Disease Stage 2, Radiographic Contrast Agent Nephropathy
N-Acetyl Cystein and Contrast Nephropathy
There are many controversies about the role of N-Acetyl Cystein in preventing of contrast nephropathy. These contradictory results may be due to different criteria for patients' selection, different end points, different type and…
- Trial name
- NCT01820195
- Testing
- Oral N-Acetyl Cystein, IV N-Acetyl Cystein
- Where
- Iran
- Volunteers
- 549 people
- Sponsor
- Imam Khomeini Hospital
Radiographic Contrast Agent Nephropathy
Does Bicarbonate in Addition to Theophylline Reduce CIN?
Contrast-induced nephropathy (CIN) is the third most frequent cause of hospital-acquired acute renal failure. Different regimes in the prophylaxis of CIN have been investigated in the last years.
- Trial name
- NCT02643602
- Testing
- Hydration with bicarbonate in addition to theophylline, Hydration with sodium chloride in addition to theophylline
- Volunteers
- 152 people
- Sponsor
- Technical University of Munich
Radiographic Contrast Agent Nephropathy
Contrast Media Reduction and Removal in Patients With Chronic Kidney Disease (CKD) (PRESERV)
The purpose of this clinical trial is to demonstrate the efficacy and safety of the Osprey Medical CINCOR™ Contrast Removal System.
- Trial name
- NCT01168024
- Testing
- CINCOR™ System and contrast conservation unit (CCS-1), Standard of Care plus peri-procedural hydration
- Where
- 21 sites in United States, Germany
- Volunteers
- 16 people
- Sponsor
- Osprey Medical, Inc
Acute Kidney Injury
Role of Biomarkers in Predicting Contrast-induced Acute Kidney Injury in Critically Ill Patients
Title: "Role of biomarkers in predicting contrast-induced acute kidney injury in critically ill patients: a prospective observational study" Objective: To analyse the role of plasma and urinary biomarkers (Neutrophil…
- Trial name
- NCT02430844
- Where
- India
- Volunteers
- 85 people
- Sponsor
- Sanjay Gandhi Postgraduate Institute of Medical Sciences
Contrast Induced Nephropathy
Contrast Agent-associated Nephrotoxicity in Intensive Care Unit Patients
The use of N-acetylcysteine and ascorbic acid reduce the incidence of radiographic contrast agent induced reduction in renal function in Intensive Care Unit patients.
- Trial name
- ICU (NCT01017796)
- Testing
- N-acetylcysteine and ascorbic acid
- Volunteers
- 100 people
- Sponsor
- University of Thessaly
Radiographic Contrast Agent Nephropathy
Renin-angiotensin-aldosterone System (RAAS) Blockade and Contrast Induced Nephropathy
The aim of the current study is to evaluate prospectively whether concomitant administration of renin-angiotensin-aldosterone system (RAAS) blockers (namely ACE-I and ARBs') influence the change in estimated glomerular filtration…
- Trial name
- NCT01525888
- Testing
- stop angiotensin converting enzyme inhibitor or angiotensin receptor blocker (ACE-I/ARB)
- Volunteers
- 100 people
- Sponsor
- Soroka University Medical Center
Radiographic Contrast Agent Nephropathy
Efficacy of Dexmedetomidine in Preventing Contrast Induced Nephropathy
The aim of this study was to evaluate the effects of dexmedetomidine on renal function, hormonal and hemodynamic parameters in contrast media induced diabetic patients.
- Trial name
- NCT02137863
- Testing
- Dexmedetomidine, 0.9 % NaCl
- Volunteers
- 60 people
- Sponsor
- TC Erciyes University
Chronic Kidney Disease
DyeVert™ Plus Contrast Reduction System Multicenter Observational Study
This is a prospective, single arm, multi-center, observational clinical study of the DyeVert Plus System. The DyeVert Plus System is an FDA-cleared device designed to reduce contrast media volume delivered during angiography and…
- Trial name
- NCT03715452
- Testing
- DyeVert Plus Contrast Reduction System
- Where
- 8 sites in United States
- Volunteers
- 114 people
- Sponsor
- Osprey Medical, Inc
Radiographic Contrast Agent Nephropathy, Aortic Valve Stenosis With Insufficiency
The Effect of the Forced Diuresis With Matched Hydration in Reducing Acute Kidney Injury During TAVI
Evaluating whether forced diuresis with matched hydration will reduce the risk of contrast induced nephropathy in patients undergoing Transcatheter Aortic Valve Implantation (TAVI).
- Trial name
- REDUCE-AKI (NCT01866800)
- Testing
- Renal Guard, Conventional Treatment
- Where
- Israel
- Volunteers
- 136 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Radiographic Contrast Agent Nephropathy
RenalGuard System for Prevention of Contrast Induced Nephropathy
The purpose of this study is to determine whether hydration with intravenous saline matched with urine output, using the device RenalGuard is superior to standard hydration with saline to prevent contrast-induced nephropathy.
- Trial name
- REPRECIN (NCT02029820)
- Testing
- RenalGuard
- Where
- Brazil
- Volunteers
- 210 people
- Sponsor
- Hospital Sao Lucas da PUCRS
Radiographic Contrast Agent Nephropathy
Oral Versus Intravenous Hydration to Prevent Contrast Induced Nephropathy
The purpose of this study is to investigate if home-hydration is a non inferior alternative for in-hospital hydration in the prevention of Contrast Induced Nephropathy in high risk patients.
- Trial name
- INOVATIO (NCT01654328)
- Testing
- Sodium chloride tablets, Isotonic saline intravenously
- Where
- Netherlands
- Volunteers
- 256 people
- Sponsor
- Prof. Dr. J. Wetzels